|
0001590560
false
00-0000000
0001590560
2019-11-04
2019-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 5, 2019
uniQure N.V.
(Exact Name of Registrant as Specified in
Charter)
|
The Netherlands
|
|
001-36294
|
|
N/A
|
(State or Other
Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Paasheuvelweg 25a,
1105 BP Amsterdam, The Netherlands
|
|
N/A
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: +31-20-566-7394
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
|
Ordinary Shares, par value €0.05 per share
|
|
QURE
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On November 5, 2019, uniQure N.V. (the “Company”)
issued a press release announcing the issuance by the U.S. Patent and Trademark Office of a new patent providing for further protection
of the Company’s Padua and Padua-related variants of Factor IX in gene therapy. A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
In accordance with General Instruction B.2 of Form 8-K, the
information set forth in this Item 7.01 and Exhibit 99.1 are “furnished” and shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibit
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
UNIQURE N.V.
|
|
|
|
|
|
|
|
Date: November 5, 2019
|
By:
|
/S/ MATTHEW KAPUSTA
|
|
|
|
Matthew Kapusta
|
|
|
|
Chief Executive Officer and Chief Financial Officer
|
| 
